Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, discusses recent developments in the treatment of neurodegenerative diseases. Most treatments under development for diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis target the proteins thought to be involved in the pathophysiology of the disease, including anti-amyloid- β, anti-tau, and anti-synuclein therapies. However, evidence suggests that targeting proteins does not give patients the best overall outcome or best risk-benefit, which highlights the importance of developing new therapies and approaches for neurodegenerative diseases. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.